MedTrace Logo

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

NCT07123350 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-05-08

No results posted yet for this study

Summary

The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration.

Patients with IBD who are starting subcutaneous vedolizumab administration between September 1, 2023, and March 31, 2025, as part of normal patient care, will be retrospectively reviewed and analyzed.

Conditions

  • Inflammatory Bowel Disease (IBD)
  • Crohn&Amp;#39;s Disease (CD)
  • Ulcerative Colitis (UC)

Interventions

DRUG

Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care

This study does not include any subject enrollment or randomization. This is a retrospective cohort review of patients referred to start subcutaneous vedolizumab from a VUMC IBD provider.

Sponsors & Collaborators

Principal Investigators

  • Miranda Z. Murray, PharmD · Vanderbilt University Medical Center

  • Autumn D. Zuckerman, PharmD · Vanderbilt University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-16
Primary Completion
2026-03-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07123350 on ClinicalTrials.gov